Overview Dividends

(SKWD) Skyward Specialty Insurance - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8309401029

General, Auto, Property, Workers, Liability

Property & Casualty Insurance
Market Cap in USD: 1,969m

IPO / Inception: 2023-01-13
Return 12m vs S&P 500: -12.5%

EPS (Earnings per Share)

EPS CAGR: 65.89%
EPS Trend: 92.9%

Last SUE: 4.00
Qual. Beats: 4

Revenue

Rev. CAGR: 29.47%
Rev. Trend: 98.5%

Last SUE: 4.00
Qual. Beats: 1

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	34.3%
Value at Risk 5%th	54.6%
Relative Tail Risk	-3.17%

Reward TTM
Sharpe Ratio	0.17
Alpha	-7.20
CAGR/Max DD	1.52

Character TTM
Hurst Exponent	0.356
Beta	0.595
Beta Downside	0.572

Drawdowns 3y
Max DD	30.95%
Mean DD	8.27%
Median DD	4.95%

Description: SKWD Skyward Specialty Insurance November 11, 2025

Skyward Specialty Insurance Group, Inc. (NASDAQ: SKWD) is a Houston-based holding company that underwrites a broad suite of U.S. commercial property-and-casualty lines, including general and excess liability, professional liability, commercial auto, workers’ compensation, surety, agriculture, credit, and niche cannabis insurance. The firm, originally incorporated in 2006 as Houston International Insurance Group, rebranded to its current name in November 2020.

According to its most recent 10-K (FY 2023), Skyward reported net written premiums of roughly $420 million, a combined ratio of 93.5% (indicating underwriting profitability), and a return on equity (ROE) of about 12.8%-both above the industry median for specialty insurers. The balance sheet shows a leverage ratio of 1.6 ×, comfortably within regulatory limits, and an investment portfolio yielding ~4.2% after fees.

Key drivers for Skyward’s performance include: (1) the continued expansion of commercial construction and infrastructure spending in the United States, which fuels demand for property and liability coverage; (2) heightened climate-related loss exposure that pressures pricing and loss reserves across the P&C sector; and (3) the rapid growth of the legal cannabis market, where specialized insurance remains under-served and offers premium-earning opportunities.

For a deeper, data-rich analysis of SKWD’s valuation metrics and scenario modeling, you may find ValueRay’s platform a useful next step.

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (141.2m TTM) > 0 and > 6% of Revenue (6% = 80.3m TTM)

FCFTA 0.08 (>2.0%) and ΔFCFTA -2.93pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 160.7% (prev 129.8%; Δ 30.86pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.08 (>3.0%) and CFO 378.2m > Net Income 141.2m (YES >=105%, WARN >=100%)

Net Debt (-40.5m) to EBITDA (190.1m) ratio: -0.21 <= 3.0 (WARN <= 3.5)

Current Ratio 6.39 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (41.9m) change vs 12m ago 1.07% (target <= -2.0% for YES)

Gross Margin 28.12% (prev 46.88%; Δ -18.76pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 32.66% (prev 30.27%; Δ 2.39pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 24.36 (EBITDA TTM 190.1m / Interest Expense TTM 7.72m) >= 6 (WARN >= 3)

Altman Z'' 3.60

(A) 0.47 = (Total Current Assets 2.55b - Total Current Liabilities 398.9m) / Total Assets 4.59b

(B) 0.05 = Retained Earnings (Balance) 223.9m / Total Assets 4.59b

(D) 0.06 = Book Value of Equity 233.9m / Total Liabilities 3.63b

Total Rating: 3.60 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 87.43

1. Piotroski 4.0pt

2. FCF Yield 61.00%

3. FCF Margin 27.76%

4. Debt/Equity 0.12

5. Debt/Ebitda -0.21

6. ROIC - WACC (= 6.50)%

7. RoE 16.11%

8. Rev. Trend 98.46%

9. EPS Trend 92.91%

What is the price of SKWD shares?

As of January 09, 2026, the stock is trading at USD 47.22 with a total of 380,525 shares traded.
Over the past week, the price has changed by -2.88%, over one month by +0.98%, over three months by -3.57% and over the past year by +3.53%.

Is SKWD a buy, sell or hold?

Skyward Specialty Insurance has received a consensus analysts rating of 3.83. Therefore, it is recommended to buy SKWD.

Strong Buy: 3
Buy: 4
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the SKWD price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	63.5	34.5%
Analysts Target Price	63.5	34.5%
ValueRay Target Price	56.9	20.5%

SKWD Fundamental Data Overview January 06, 2026

Market Cap USD = 1.97b (1.97b USD * 1.0 USD.USD)
P/E Trailing = 14.4273
P/E Forward = 10.6838
P/S = 1.4741
P/B = 2.0475
P/EG = 0.7245
Beta = 0.539
Revenue TTM = 1.34b USD
EBIT TTM = 188.1m USD
EBITDA TTM = 190.1m USD
Long Term Debt = 76.6m USD (from longTermDebt, last quarter)
Short Term Debt = 43.0m USD (from shortTermDebt, last quarter)
Debt = 119.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -40.5m USD (from netDebt column, last quarter)
Enterprise Value = 608.8m USD (1.97b + Debt 119.6m - CCE 1.48b)
Interest Coverage Ratio = 24.36 (Ebit TTM 188.1m / Interest Expense TTM 7.72m)
FCF Yield = 61.00% (FCF TTM 371.4m / Enterprise Value 608.8m)
FCF Margin = 27.76% (FCF TTM 371.4m / Revenue TTM 1.34b)
Net Margin = 10.55% (Net Income TTM 141.2m / Revenue TTM 1.34b)
Gross Margin = 28.12% ((Revenue TTM 1.34b - Cost of Revenue TTM 961.7m) / Revenue TTM)
Gross Margin QoQ = 31.18% (prev 29.58%)
Tobins Q-Ratio = 0.13 (Enterprise Value 608.8m / Total Assets 4.59b)
Interest Expense / Debt = 1.61% (Interest Expense 1.92m / Debt 119.6m)
Taxrate = 24.19% (14.6m / 60.5m)
NOPAT = 142.6m (EBIT 188.1m * (1 - 24.19%))
Current Ratio = 6.39 (Total Current Assets 2.55b / Total Current Liabilities 398.9m)
Debt / Equity = 0.12 (Debt 119.6m / totalStockholderEquity, last quarter 961.4m)
Debt / EBITDA = -0.21 (Net Debt -40.5m / EBITDA 190.1m)
Debt / FCF = -0.11 (Net Debt -40.5m / FCF TTM 371.4m)
Total Stockholder Equity = 876.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.07% (Net Income 141.2m / Total Assets 4.59b)
RoE = 16.11% (Net Income TTM 141.2m / Total Stockholder Equity 876.5m)
RoCE = 19.73% (EBIT 188.1m / Capital Employed (Equity 876.5m + L.T.Debt 76.6m))
RoIC = 14.31% (NOPAT 142.6m / Invested Capital 996.1m)
WACC = 7.81% (E(1.97b)/V(2.09b) * Re(8.21%) + D(119.6m)/V(2.09b) * Rd(1.61%) * (1-Tc(0.24)))
Discount Rate = 8.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.85%
[DCF Debug] Terminal Value 80.91% ; FCFE base≈381.5m ; Y1≈470.6m ; Y5≈802.9m
Fair Price DCF = 326.6 (DCF Value 13.22b / Shares Outstanding 40.5m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 92.91 | EPS CAGR: 65.89% | SUE: 4.0 | # QB: 4
Revenue Correlation: 98.46 | Revenue CAGR: 29.47% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.13 | Chg30d=+0.026 | Revisions Net=+3 | Analysts=9
EPS next Year (2026-12-31): EPS=4.74 | Chg30d=+0.154 | Revisions Net=+6 | Growth EPS=+23.7% | Growth Revenue=+27.7%

Additional Sources for SKWD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle